← Leaderboards
Evan Newell
Fred Hutchinson Cancer Research Center
$4,360,128
Attributed
$4,360,128
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,360,128 · 2
By mechanism
R01$3,042,380 · 1
P01$1,317,748 · 1
Top collaborators
No co-investigators on record.
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Michael Leo Leblanc$73,215,863
- Jerald P Radich$16,007,933
- Effie W Petersdorf$50,293,518
- Ziding Feng$59,366,183
- Paul J Martin$18,480,958
Others in their field
Other Emerging Leaders on “T-Lymphocyte”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Crystal Mackall · Children'S Hosp Of Philadelphia$16,367,876
- Wilton B Williams · Duke University$16,226,847
- Gary Fanger · Rise Therapeutics, Llc$15,372,982
- Aaron Esser-Kahn · University Of Chicago$13,378,548
Research focus
T-LymphocyteImmuneSingle Cell SequencingTumorProtein ExpressionGene Expression ProfileImmunohistochemistrySamplingTissuesTumor MicroenvironmentT Cell Receptor Repertoire SequencingCellsMultiple OmicsCytometryAmerican Association Of Cancer ResearchDiagnosisAnti-Pd1 TherapyClone CellsCohortEnrollmentCellular ImagingCharacteristicsAftercareClinically Relevant
Grant awards (8)
Core C: High Dimensional Cellular and Spatial Analysis$658,874
P01 · FY2025 · CA · contact PI
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma$615,760
R01 · FY2025 · CA · contact PI
Core C: High Dimensional Cellular and Spatial Analysis$658,874
P01 · FY2024 · CA · contact PI
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma$584,972
R01 · FY2024 · CA · contact PI
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma$603,444
R01 · FY2023 · CA · contact PI
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma$603,444
R01 · FY2022 · CA · contact PI
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma$355,610
R01 · FY2021 · CA · contact PI
The roles of EBV-specific T cells in response to checkpoint blockade immunotherapy of EBV-driven nasopharyngeal carcinoma$279,150
R01 · FY2021 · CA · contact PI